To identify predictors for 2 risk measures—“proven invasive bacterial infection or culture-negative sepsis (IBD)” and “clinical complications (CC)”—in pediatric cancer patients with fever and neutropenia (FN).
Records of 390 patients with FN hospitalized over 2 years were reviewed. For the 332 who met inclusion criteria, one FN episode was randomly selected. Independent predictors at presentation were analyzed using multiple regression models. Optimal cut-off risk prediction scores were determined. These models were validated by bootstrap analysis.
Patients' median age was 6.0 years; 66% had an underlying diagnosis of leukemia. Independent predictors of IBD (n = 56) were absolute neutrophil count <100, temperature at presentation ≥39.0°C, “sick” clinical appearance, and underlying diagnosis of acute myeloid leukemia. A total weighted score <24 reliably identified patients at low risk for IBD. Independent predictors of CC (n = 47) were relapse of malignancy, non-white race, “sick” clinical appearance, and underlying diagnosis of acute myeloid leukemia. A total weighted score <19 predicted patients at low risk for CC. Of those misclassified as low risk, 11 of 12 with IBD and 3 of 9 with CC had the outcome within 24 hours of presentation. Of the remaining patients classified as low-risk for IBD and CC, 99.5% and 97.1%, respectively, remained outcome-free after 24 hours of observation.
This study identifies predictors of infection/complications in pediatric patients with FN, establishes clinical cut-off scores and highlights the importance of the initial clinical impression and 24 hours of observation. These prediction models warrant prospective validation.
SUPPLEMENTAL DIGITAL CONTENT IS AVAILABLE IN THE TEXT.
From the *Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN; Departments of †Pediatrics and ‡Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; and §Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.
Accepted for publication October 1, 2009.
Supported by a National Institutes of Health grant (CA21765) and the American Lebanese Syrian Associated Charities (ALSAC).
Presented as a poster at the 45th Annual Meeting of Infectious Diseases Society of America (IDSA), San Diego, CA, October 2007. Another part was presented as a poster at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/45th Annual Infectious Diseases Society of America (IDSA) Meeting, Washington, DC, October 2008.
The authors report no conflicts of interest.
Address for correspondence: Hana Hakim, MD, Department of Infectious Diseases, Mail Stop 600, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678. E-mail: Hana.Hakim@stjude.org.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).